TIL Healthcare Private Limited

TIL Healthcare Private Limited, established on January 25, 1991, is a privately held pharmaceutical company headquartered in Chennai, Tamil Nadu, India. The company is registered under the Corporate Identification Number (CIN) U24231TN1991PTC020206. As of March 31, 2024, TIL Healthcare reported an authorized capital of ₹5.00 crore and a paid-up capital of ₹2.31 crore. The company employs approximately 230 professionals, reflecting its commitment to quality and innovation in the pharmaceutical sector.

TIL Healthcare specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Over the years, the company has expanded its global footprint, exporting products to over 54 countries across Africa, Asia, Latin America, Europe, and the CIS region. This extensive reach underscores TIL Healthcare's dedication to enhancing global health outcomes through high-quality pharmaceutical products.

TIL Healthcare operates multiple state-of-the-art manufacturing facilities, including a significant plant in the Sri City Special Economic Zone (SEZ) in Tada, Andhra Pradesh. This facility has undergone substantial expansion, tripling its capacity to meet the growing global demand for its products. The manufacturing plants are approved by various health regulatory authorities, including EU-GMP, TGA Australia, FDA Ghana, and NAFDAC Nigeria, along with cGMP and ISO certifications.

The company's manufacturing capabilities encompass a diverse range of dosage forms, such as tablets, capsules, soft gels, liquids, powders, injectables, suppositories, effervescents, and drops. This versatility enables TIL Healthcare to cater to a wide array of therapeutic needs, reinforcing its position as a comprehensive pharmaceutical manufacturer.

TIL Healthcare is led by Managing Director Mr. Kapil Jhaver, who has been instrumental in steering the company towards significant growth and global expansion. Under his leadership, the company has achieved notable milestones, including the expansion of its manufacturing facilities and the establishment of a strong presence in over 54 countries.

The company's leadership team also includes Director Mr. Rangarajan Vijayaragavan, who has been associated with TIL Healthcare since March 17, 2022. Additionally, Mr. Kapil Jhaver serves as an Additional Director, contributing to the strategic direction and operational excellence of the company.

TIL Healthcare has established a robust presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold certifications from esteemed regulatory bodies such as the European Union's Good Manufacturing Practice (EU GMP) and the Therapeutic Goods Administration (TGA) of Australia. These certifications attest to the company's adherence to stringent quality standards required for market access in these regions.

In the United States, TIL Healthcare has made significant strides by obtaining FDA approvals for its manufacturing facilities and product registrations. This achievement facilitates the company's entry into the U.S. market, allowing it to supply high-quality pharmaceutical products to meet the needs of American consumers.

The company's commitment to regulatory compliance is further demonstrated by its successful submissions to Denmark and Hungary in 2025, expanding its reach within the European market. These efforts reflect TIL Healthcare's dedication to meeting the diverse regulatory requirements of various international markets.

TIL Healthcare has strategically penetrated emerging markets in Africa, Latin America, and Southeast Asia, exporting its products to over 54 countries across these regions. The company's adherence to international quality standards, as evidenced by certifications such as EU GMP and TGA, has facilitated its acceptance in these markets. Additionally, TIL Healthcare's commitment to corporate social responsibility (CSR) initiatives, including the establishment of the TIL Foundation in 2019, demonstrates its dedication to contributing positively to the communities it serves.

TIL Healthcare's geographic strategy is characterized by a diversified approach, with exports spanning over 54 countries across continents. This broad market presence mitigates concentration risk and positions the company to leverage growth opportunities in various regions. The company's strategic direction focuses on expanding its footprint in both regulated and emerging markets, ensuring a balanced and sustainable growth trajectory.

TIL Healthcare has achieved FDA facility registrations, enabling it to manufacture and export pharmaceutical products to the United States. The company's commitment to quality is further demonstrated by its adherence to current Good Manufacturing Practice (cGMP) standards, ensuring that its products meet the stringent requirements set by the FDA. While specific details regarding approved Abbreviated New Drug Applications (ANDAs) and Drug Master File (DMF) filings are not publicly disclosed, the company's FDA registrations indicate a proactive approach to compliance and market access.

TIL Healthcare's manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practice (WHO GMP) and the European Union's Good Manufacturing Practice (EU GMP). These certifications affirm the company's adherence to international quality standards, facilitating its entry into various global markets. The EU GMP certification, obtained in 2023, underscores the company's commitment to maintaining high-quality manufacturing processes.

In India, TIL Healthcare holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), authorizing it to produce pharmaceutical products for both domestic and international markets. The company's compliance with Indian regulatory standards ensures that its products meet the safety and efficacy requirements set by the CDSCO. Additionally, TIL Healthcare has obtained export No Objection Certificates (NOCs), facilitating the export of its products to various countries.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to TIL Healthcare by regulatory authorities. This absence suggests that the company maintains a strong compliance record and adheres to the regulatory standards set by health authorities.

TIL Healthcare operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. While specific market share data for TIL Healthcare's products is not publicly disclosed, the company's extensive product portfolio and global presence position it as a significant player in the market. The company's adherence to international quality standards, as evidenced by certifications such as EU GMP and TGA, enhances its competitiveness in regulated markets.

TIL Healthcare's key differentiators include its diverse product portfolio, encompassing various dosage forms such as tablets, capsules, injectables, liquids, powders, and effervescents. The company's commitment to quality is demonstrated by its adherence to international standards, with certifications from EU GMP, TGA, and ISO. Additionally, TIL Healthcare's strategic focus on both regulated and emerging markets allows it to leverage growth opportunities across different regions.

TIL Healthcare's current strategic direction emphasizes the expansion of its product portfolio and market presence. The company's focus on both finished pharmaceutical formulations and contract manufacturing services (CDMO) enables it to cater to a wide range of client needs. Looking ahead, TIL Healthcare aims to strengthen its position in existing markets while exploring new opportunities, particularly in emerging regions, to drive sustainable growth and innovation.

TIL Healthcare has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $3.4 million USD and 70 shipments across two products in 2022-2026. The company's adherence to international quality standards, as evidenced by certifications such as EU GMP and TGA, indicates a high level of reliability. The absence of publicly available records indicating regulatory non-compliance further supports the company's reputation as a dependable supplier.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the company's FDA facility registration to ensure compliance with U.S. regulations.

• EU GMP Certification: Verify the EU GMP certification to ensure adherence to European manufacturing standards.

• TGA